Literature DB >> 34321496

Association between comorbid asthma and prognosis of critically ill patients with severe sepsis: a cohort study.

Jinju Huang1, Jurong Zhang1, Faxia Wang1, Jiezhu Liang1, Qinchang Chen2, Zhuandi Lin3.   

Abstract

Basic research suggests some contributing mechanisms underlying asthma might at the same time benefit patients with asthma against sepsis, while the potential protective effect of comorbid asthma on prognosis of sepsis has not been well studied in clinical research. The study aimed to assess the association between comorbid asthma and prognosis in a cohort of patients admitted to intensive care unit (ICU) with severe sepsis. Patients with severe sepsis admitted to ICUs were included from the MIMIC-III Critical Care Database, and categorized as patients without asthma, patients with stable asthma, and patients with acute exacerbation asthma. The primary study outcome was 28-day mortality since ICU admission. Difference in survival distributions among groups were evaluated by Kaplan-Meier estimator. Multivariable Cox regression was employed to examine the association between comorbid asthma and prognosis. A total of 2469 patients with severe sepsis were included, of which 2327 (94.25%) were without asthma, 125 (5.06%) with stable asthma, and 17 (0.69%) with acute exacerbation asthma. Compared with patients without asthma, patients with asthma (either stable or not) had a slightly younger age (66.73 ± 16.32 versus 64.77 ± 14.81 years), a lower proportion of male sex (56.81% versus 40.14%), and a lower median SAPS II score (46 versus 43). Patients with acute exacerbation asthma saw the highest 28-day mortality rate (35.29%), but patients with stable asthma had the lowest 28-day mortality rate (21.60%) when compared to that (34.42%) in patients without asthma. Consistent results were observed in Kaplan-Meier curves with a p-value for log-rank test of 0.016. After adjusting for potential confounding, compared to being without asthma, being with stable asthma was associated with a reduced risk of 28-day mortality (hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44-0.97, p = 0.0335), but being with acute exacerbation asthma was toward an increased risk of 28-day mortality (HR 1.82, 95% 0.80-4.10, p = 0.1513). E-value analysis suggested robustness to unmeasured confounding. These findings suggest comorbid stable asthma is associated with a better prognosis in critically ill patients with severe sepsis, while acute exacerbation asthma is associated with worse prognosis.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34321496     DOI: 10.1038/s41598-021-93907-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  36 in total

1.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

2.  Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys.

Authors:  Helena Backman; Petri Räisänen; Linnea Hedman; Caroline Stridsman; Martin Andersson; Anne Lindberg; Bo Lundbäck; Eva Rönmark
Journal:  Clin Exp Allergy       Date:  2017-07-12       Impact factor: 5.018

Review 3.  The impact of comorbid [corrected] conditions on critical illness.

Authors:  Annette M Esper; Greg S Martin
Journal:  Crit Care Med       Date:  2011-12       Impact factor: 7.598

4.  Systemic inflammatory response syndrome criteria in defining severe sepsis.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo
Journal:  N Engl J Med       Date:  2015-03-17       Impact factor: 91.245

5.  Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC).

Authors:  C K W Lai; R Beasley; J Crane; S Foliaki; J Shah; S Weiland
Journal:  Thorax       Date:  2009-02-22       Impact factor: 9.139

6.  Respiratory symptoms/diseases prevalence is still increasing: a 25-yr population study.

Authors:  Sara Maio; Sandra Baldacci; Laura Carrozzi; Francesco Pistelli; Anna Angino; Marzia Simoni; Giuseppe Sarno; Sonia Cerrai; Franca Martini; Martina Fresta; Patrizia Silvi; Francesco Di Pede; Massimo Guerriero; Giovanni Viegi
Journal:  Respir Med       Date:  2015-11-14       Impact factor: 3.415

7.  Allergies are still on the rise? A 6-year nationwide population-based study in Korea.

Authors:  Byung-Keun Kim; Ju-Young Kim; Min-Koo Kang; Min-Suk Yang; Heung-Woo Park; Kyung-Up Min; Sang-Heon Cho; Hye-Ryun Kang
Journal:  Allergol Int       Date:  2015-12-11       Impact factor: 5.836

8.  Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database.

Authors:  M Shankar-Hari; D A Harrison; G D Rubenfeld; K Rowan
Journal:  Br J Anaesth       Date:  2017-10-01       Impact factor: 9.166

9.  Association Between Comorbid Chronic Obstructive Pulmonary Disease and Prognosis of Patients Admitted to the Intensive Care Unit for Non-COPD Reasons: A Retrospective Cohort Study.

Authors:  Wencheng Huang; Ruijie Xie; Yuancheng Hong; Qingui Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-02-07

Review 10.  Systematic review of worldwide variations of the prevalence of wheezing symptoms in children.

Authors:  Swatee P Patel; Marjo-Riitta Järvelin; Mark P Little
Journal:  Environ Health       Date:  2008-11-10       Impact factor: 5.984

View more
  1 in total

1.  A comparison of impact of comorbidities and demographics on 60-day mortality in ICU patients with COVID-19, sepsis and acute respiratory distress syndrome.

Authors:  Björn Ahlström; Robert Frithiof; Ing-Marie Larsson; Gunnar Strandberg; Miklos Lipcsey; Michael Hultström
Journal:  Sci Rep       Date:  2022-09-20       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.